Janus

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

Retrieved on: 
Wednesday, November 1, 2023
Janus, Online, Woman, Zoledronic acid, Biologic, Rheumatology, Population Health Management, Metabolic bone disease, Spondyloarthropathy, Systemic disease, Thrombosis, MRI, ANCA, Health care, Syndrome, Immunomodulation, Domain, Metabolism, Risk, Vasculitis, Inflammation, Osteoporosis, Adalimumab, Janus kinase inhibitor, Biomarker, Crystal, Rheumatoid arthritis, Alendronic acid, Social, Psoriatic arthritis, Use, Driver, Etanercept, PST, Metric, State, Paint, Pharmaceutical industry, Medical imaging, Health insurance, Book, Dentistry, Dietary supplement, Denosumab, Patient, Hand

THOUSAND OAKS, Calif., Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

Key Points: 
  • Abstract #2161, Poster Session C: RA – Treatments Poster III, Tuesday, Nov. 14 from 9-11am PST
    Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Abstract #0441, Poster Session A: RA – Treatments Poster I, Sunday, Nov. 12 from 9-11am PST
    Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
    Abstract #0236, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
    Abstract #0237, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0239, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0242, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
    Abstract #1102, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1103, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1107, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1108, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Real-world Trends in the Use of Immunomodulation as Co-Therapy to Pegloticase: Claims-Based Findings Since 2016
    Abstract #1123, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1145, Poster Session B: Miscellaneous Rheumatic & Inflammatory Diseases Poster II, Monday, Nov. 13 from 9-11am PST
    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
    Abstract #1691, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 5-5:10pm PST
    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Abstract #1690, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 4:45-4:55pm PST
    Abstract #0966, Poster Session B: Epidemiology & Public Health Poster II, Monday Nov. 13 from 9-11am PST
    Abstract #1041, Poster Session B: Imaging of Rheumatic Diseases Poster I, Monday Nov. 13 from 9-11am PST
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients With Early Oligoarticular Psoriatic Arthritis: 16-Week Results From FOREMOST
    Abstract #1413, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Abstract #1414, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
    Abstract #2528, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:15-4:25pm PST
    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2529, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:30-4:40pm PST
    Comparative Effectiveness of Denosumab versus Alendronate among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2008, Poster Session C: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0683, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0684, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0685, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0686, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #2379, Poster Session C: Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0171, Poster Session A: Health Services Research Poster I, Sunday, Nov. 12 from 9-11am PST
    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren's Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
    Abstract #1636, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Abstract #1638, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren's Disease: Results from a Multinational, Real-World Survey
    Abstract #1369, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjögren's Syndrome
    Abstract #1379, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Disease Burden of Patients with Primary Sjögren's Disease: Results from a Multinational Real-World Survey
    Abstract #2179, Poster Session C: Sjögren's Syndrome – Basic & Clinical Science Poster II, Tuesday, Nov. 14 from 9-11am PST
    Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
    Abstract #0688, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST

Start a wave of generosity Nov. 1 by giving early for Colorado Gives Day

Retrieved on: 
Friday, October 27, 2023
Janus, Digital, 5280, PC, Noodles & Company, 9News, Southwest Airlines, ESG, River, CHFA, Corporation, State, First Bank, Pet, Colorado Public Radio, Radio, Advertising, Rocky Mountain PBS, Delta Dental, Love, Cancer, IHeartRadio, Movement, JPMorgan Corporate Challenge, Private investigator, Entravision Communications, Social, Comcast, Amazon

Colorado Gives Day is easily the best day to give.

Key Points: 
  • Colorado Gives Day is easily the best day to give.
  • "We all have the things we care about and on Colorado Gives Day, you can give to what matter most to you," said Kelly Dunkin, president and CEO of Colorado Gives Foundation, the organization behind Colorado Gives Day.
  • "FirstBank's continued support of Colorado Gives Day demonstrates our commitment to investing in the communities we love and serve."
  • "Let's take 'doing good' to new elevations this Colorado Gives Day to discover how much good we can create together," added Dunkin.

Shanghai Jiao Tong University's "Lui Che Woo Science Park" officially Inaugurated, Hong Kong Secondary School Students Witness the Advancement of Mainland China's High-tech Development

Retrieved on: 
Friday, October 20, 2023
Janus, Knowledge, Faculty, Shanghai Synchrotron Radiation Facility, SJTU, Shanghai Jiao Tong University, GFA, CPPCC, Physics, STEM, Housing, K. Wah International, Lui, Mainland China, University, Medicine, Mathematics, Biology, Florida Board of Governors, Shanghai Science Association for Young Talents, United Front Work Department, Research, CPC, Data storage, Learning, Jiaotong University, Birmingham City University Faculty of Computing, Engineering and the Built Environment, Park, Tung Wah Group of Hospitals, Environment, Trustee, City, Student, Tutoring, Civil engineering, Janitor, Management, Video game, Creative industries, Tourism, Engineering, Science, Hospital, Zhangjiang

In attendance were Hong Kong secondary school students, who were part of the "KWIH and TWGHs Study Tour at Shanghai Jiao Tong University 2023".

Key Points: 
  • In attendance were Hong Kong secondary school students, who were part of the "KWIH and TWGHs Study Tour at Shanghai Jiao Tong University 2023".
  • Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilisation interacts with media.
  • Hong Kong secondary school students who joined the "KWIH and TWGHs Study Tour at Shanghai Jiao Tong University 2023" visit Shanghai K. Wah Centre.
  • Their presence added significance to this momentous milestone in fostering the development and exchange of science and technology between Shanghai and Hong Kong.

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Thursday, October 26, 2023
Janus, Patient, FDA, Crohn's & Colitis Foundation, Eli Lilly and Company, Headache, Icahn School of Medicine at Mount Sinai, NYSE, Food, Lower respiratory tract infection, UC, UC-2, Hope, LLY, NRS, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Jaki, Ulcerative colitis, Rash, UC-1, Mount Sinai, Hepatotoxicity, Arthralgia, Immunology, Tuberculosis, European, Pharmaceutical industry, Lilly, Gastroenterology, Medicine

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Key Points: 
  • "Today's approval represents a novel scientific advancement, providing a treatment that may offer relief from three key symptoms—stool frequency, rectal bleeding and bowel urgency—regardless of past biologic use."
  • All patients in the LUCENT program had past treatments, including biologic treatments, that did not work, stopped working or that they could not tolerate.
  • Patients in steroid-free clinical remission were steroid-free for at least three months prior to the end of the 52-week assessment.
  • "Bowel urgency is one of the most disruptive symptoms for patients with ulcerative colitis," said Michael Osso, president and chief executive officer, Crohn's & Colitis Foundation.

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Janus, Medical Affairs Bureau, Lineage Cell Therapeutics, AMD, AAO, Cell, Geographic atrophy, OD, RPE, Division, San Francisco Marriott Marquis, American Academy, GA, American Academy of Ophthalmology, Lineage, Annual general meeting, Macular degeneration, Roche, TASE, CFA, NYSE American, San Francisco, Therapy, Patient, Food and Drug Administration, Pharmaceutical industry, Ophthalmology, Genentech

In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .

Key Points: 
  • In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .
  • Eyecelerator will occur prior to the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and will be held at the San Francisco Marriott Marquis on Thursday, November 2nd, 2023.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

Janus International Group to Report Third Quarter 2023 Results on November 6, 2023

Retrieved on: 
Monday, October 23, 2023
Hardware, Building Systems, Commercial Building & Real Estate, Technology, Construction & Property, Janus, Domestic, JBI, Conference, NYSE, Webcast, International, International Marxist Group, Video game

Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading global provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, announced today that the Company will release its third quarter 2023 financial results before the market opens on Monday, November 6, 2023.

Key Points: 
  • Janus International Group, Inc. (NYSE: JBI) (“Janus” or the “Company”), a leading global provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, announced today that the Company will release its third quarter 2023 financial results before the market opens on Monday, November 6, 2023.
  • A webcast and conference call will be held that same day at 10:00 a.m.
  • ET to review the Company’s third quarter results and conduct a question-and-answer session.
  • Upon dialing in, please request to join the Janus International Group Third Quarter 2023 Earnings Conference Call.

First Trust Dynamic Europe Equity Income Fund Declares its Monthly Common Share Distribution of $0.07 Per Share for November

Retrieved on: 
Monday, October 23, 2023
Professional Services, Finance, Janus, ARCA, Terrorism, NYSE, Infection, US, FINRA, ERISA, Internal Revenue Code, FTA, Federal Reserve, Fraud, AIB (NI), Investment, REIT, Judgement, European Central Bank, Federal, Central bank, Real estate investment trust, City, NYSE Arca, Risk, FTP, COVID-19, Indian stock exchange, Fund, Uncertainty, Economic development, NAV, Social change, European, New York Stock Exchange, Janus Henderson, Security (finance), Life insurance, Financial adviser, Bank, Financial services, Euro, EU

First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.07 per share payable on November 15, 2023, to shareholders of record as of November 2, 2023.

Key Points: 
  • First Trust Dynamic Europe Equity Income Fund (the "Fund") (NYSE: FDEU) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.07 per share payable on November 15, 2023, to shareholders of record as of November 2, 2023.
  • This distribution may consist of net investment income earned by the Fund, net short-term and long-term capital gains and/or tax deferred return of capital.
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.
  • FTA and its affiliate First Trust Portfolios L.P. ("FTP"), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services.

First Trust Announces Shareholder Approval of First Trust Dynamic Europe Equity Income Fund’s Reorganization into First Trust Active Global Quality Income ETF

Retrieved on: 
Monday, October 23, 2023
Professional Services, Finance, Janus, Suite, ARCA, NYSE, US, FINRA, FTA, ETF, News, AIB (NI), Trustee, City, NYSE Arca, FTP, Prospectus, External commercial borrowing, Security (finance), Financial adviser

As previously announced, the reorganization was approved by the Boards of Trustees of FDEU and AGQI on March 22, 2023.

Key Points: 
  • As previously announced, the reorganization was approved by the Boards of Trustees of FDEU and AGQI on March 22, 2023.
  • Subject to the satisfaction of certain customary closing conditions, the reorganization of FDEU into AGQI is expected to close on or around November 20, 2023.
  • FDEU is a diversified, closed-end management investment company that seeks to provide a high level of current income with a secondary focus on capital appreciation.
  • AGQI is an actively managed ETF that seeks income with the potential for capital growth over the longer-term.

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Pharmaceutical, Health, Janus, Tralokinumab, Patient, Adolescence, AD, Ageing, Catalog, Leo Pharma, Conference, Systematic review, Research, RWE, Meta-analysis, TRACE, Various, Disease, S. aureus, Safety, Atopic dermatitis, LEO, Pharmaceutical industry, Vaccine

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).
  • The drug is marketed in the U.S. as Adbry® for adult patients (aged 18+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • The findings are being presented across 12 posters at the 2023 Fall Clinical Dermatology Conference taking place in Las Vegas, Nevada, from October 19-22, 2023.1-12
    “We are thrilled to present such a wealth of tralokinumab-ldrm data, which will further develop our understanding of how to meet the needs of patients living with atopic dermatitis,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.
  • “The breadth and depth of LEO Pharma data being presented at the Fall Clinical Dermatology Conference this year will showcase our leadership in the medical dermatology space and our continued commitment to the whole patient community.

 Janus Henderson’s pioneering AAA CLO ETF surpasses $4 billion in AUM before third anniversary

Retrieved on: 
Wednesday, October 18, 2023
Banking, Professional Services, Finance, Janus, ASX, Innovation, NYSE, US, MBS, ETF, AAA, AUM, ALPS, BBB, City, Prospectus, Risk, Fund, Janus Henderson, CFA, Investment, JAAA, Financial adviser, Security (finance), Lisp (programming language), Bloomberg

Janus Henderson Investors (NYSE/AX: JHG) today announced that its pioneering AAA Collateralized Loan Obligation ETF, Janus Henderson AAA CLO ETF (JAAA), has surpassed $4 billion in AUM before its third anniversary, making it the largest fixed income ETF launch as measured by AUM, active or passive, of the last three years, according to Bloomberg data.

Key Points: 
  • Janus Henderson Investors (NYSE/AX: JHG) today announced that its pioneering AAA Collateralized Loan Obligation ETF, Janus Henderson AAA CLO ETF (JAAA), has surpassed $4 billion in AUM before its third anniversary, making it the largest fixed income ETF launch as measured by AUM, active or passive, of the last three years, according to Bloomberg data.
  • * Janus Henderson is now the fifth largest provider of active fixed income ETFs in the U.S by AUM as of October 16, 2023.
  • Janus Henderson has been at the forefront of active fixed income ETF innovation, offering a number of fixed income ETFs.
  • Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries.